甲托雷克萨特试验剂量使用和实验室异常的频率在开始治疗的患者
Journal of drugs in dermatology : JDD
|November 4, 2025
概括
甲状腺素试验剂量在预防皮肤病和风湿病患者的实验室异常方面具有有限的价值. 这项研究支持更新的甲状腺素启动指南,这表明大多数患者可能不需要测试剂量.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 皮肤病学和风湿病学
背景情况:
- 皮肤病学指导方针表明,在低风险患者中,可能不需要甲状腺素测试剂量.
- 很少有研究评估了测试剂量用于检测或预防甲醇毒性的有用性.
- 风湿病学指南没有提到甲状腺素测试剂量.
研究的目的:
- 为了确定从低剂量开始的患者中实验室异常的频率,口服甲状腺素.
- 为了比较接受甲状腺素测试剂量的患者和没有接受甲状腺素测试剂量的患者之间的结果.
主要方法:
- 追溯对2575名成年患者的队列分析,这些患者开始使用甲状腺素.
- 定义的试验剂量为≤15毫克与实验室在3-10天内.
- 在测试剂量和非测试剂量组之间比较4个月的2级+实验室异常.
主要成果:
- 两组之间2级+实验室异常没有显著差异 (测试剂量的6.82%与非测试剂量的4.34%,P=0.09).
- 在测试剂量组中,2.73%的人在3-10天内经历了2级+异常.
- 风湿病患者占研究人群的91%以上.
结论:
- 甲托雷克萨特测试剂量在检测或预防实验室显著异常方面似乎具有有限的价值.
- 这些发现支持不断发展的皮肤病学指南,指导使用甲状腺素测试剂量.
- 常规使用测试剂量来启动甲状腺素可能不必要.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
193
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
193
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Therapeutic Drug Monitoring: Drug Analysis Methods
171
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
171
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
176
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
176
Dosage Regimen: Multiple Oral Dosage
217
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
217
Therapeutic Drug Monitoring: Overview and Classification
293
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
293


